Bradley Canino
Stock Analyst at Stifel
(2.18)
# 1,513
Out of 4,435 analysts
71
Total ratings
39.34%
Success rate
-3.04%
Average return
Main Sectors:
Top Industries:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRUS Merus | Maintains: Buy | $65 → $90 | $53.24 | +69.05% | 6 | May 28, 2024 | |
| CELC Celcuity | Maintains: Buy | $40 | $15.80 | +153.16% | 2 | May 16, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $39 → $40 | $19.27 | +107.58% | 3 | May 9, 2024 | |
| CCCC C4 Therapeutics | Maintains: Buy | $13 → $14 | $5.00 | +180.00% | 4 | May 9, 2024 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Buy | $36 → $32 | $11.88 | +169.36% | 16 | May 8, 2024 | |
| ARVN Arvinas | Maintains: Buy | $72 → $68 | $33.14 | +105.19% | 5 | May 8, 2024 | |
| CGEM Cullinan Oncology | Initiates: Buy | $40 | $23.50 | +70.21% | 1 | May 1, 2024 | |
| BPMC Blueprint Medicines | Maintains: Buy | $120 → $130 | $105.56 | +23.15% | 5 | Apr 26, 2024 | |
| AFMD Affimed | Maintains: Hold | $1 → $5 | $4.35 | +14.94% | 4 | Apr 1, 2024 | |
| SMMT Summit Therapeutics | Initiates: Buy | $8 | $8.69 | -7.94% | 1 | Mar 26, 2024 | |
| ALXO ALX Oncology Holdings | Downgrades: Hold | $10 → $14 | $10.63 | +31.70% | 4 | Mar 8, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $35 → $55 | $32.11 | +71.29% | 4 | Feb 23, 2024 | |
| RLAY Relay Therapeutics | Maintains: Buy | $25 → $30 | $6.41 | +368.02% | 3 | Feb 22, 2024 | |
| DCPH Deciphera Pharmaceuticals | Maintains: Buy | $22 → $23 | $25.54 | -9.95% | 5 | Feb 7, 2024 | |
| NUVL Nuvalent | Reiterates: Buy | n/a | $65.62 | - | 2 | Oct 4, 2023 | |
| BDTX Black Diamond Therapeutics | Upgrades: Buy | $2 → $10 | $4.78 | +109.21% | 4 | Jun 30, 2023 | |
| KURA Kura Oncology | Maintains: Buy | $24 → $25 | $20.61 | +21.30% | 2 | Jun 12, 2023 |
Merus
May 28, 2024
Maintains: Buy
Price Target: $65 → $90
Current: $53.24
Upside: +69.05%
Celcuity
May 16, 2024
Maintains: Buy
Price Target: $40
Current: $15.80
Upside: +153.16%
Syndax Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $39 → $40
Current: $19.27
Upside: +107.58%
C4 Therapeutics
May 9, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $5.00
Upside: +180.00%
Zentalis Pharmaceuticals
May 8, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $11.88
Upside: +169.36%
Arvinas
May 8, 2024
Maintains: Buy
Price Target: $72 → $68
Current: $33.14
Upside: +105.19%
Cullinan Oncology
May 1, 2024
Initiates: Buy
Price Target: $40
Current: $23.50
Upside: +70.21%
Blueprint Medicines
Apr 26, 2024
Maintains: Buy
Price Target: $120 → $130
Current: $105.56
Upside: +23.15%
Affimed
Apr 1, 2024
Maintains: Hold
Price Target: $1 → $5
Current: $4.35
Upside: +14.94%
Summit Therapeutics
Mar 26, 2024
Initiates: Buy
Price Target: $8
Current: $8.69
Upside: -7.94%
ALX Oncology Holdings
Mar 8, 2024
Downgrades: Hold
Price Target: $10 → $14
Current: $10.63
Upside: +31.70%
Kymera Therapeutics
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $32.11
Upside: +71.29%
Relay Therapeutics
Feb 22, 2024
Maintains: Buy
Price Target: $25 → $30
Current: $6.41
Upside: +368.02%
Deciphera Pharmaceuticals
Feb 7, 2024
Maintains: Buy
Price Target: $22 → $23
Current: $25.54
Upside: -9.95%
Nuvalent
Oct 4, 2023
Reiterates: Buy
Price Target: n/a
Current: $65.62
Upside: -
Black Diamond Therapeutics
Jun 30, 2023
Upgrades: Buy
Price Target: $2 → $10
Current: $4.78
Upside: +109.21%
Kura Oncology
Jun 12, 2023
Maintains: Buy
Price Target: $24 → $25
Current: $20.61
Upside: +21.30%